NASDAQ:BSX

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific shares rose 0.7% to $74.61 by early afternoon Tuesday after a 2.8% drop Monday. New four-year Farapulse data showed higher treatment success than thermal ablation, with no long-term safety issues. Around 9.1 million shares traded by 1:15 p.m. The next major update is expected from the CHAMPION-AF trial results at ACC.26 on March 28.

10 February 2026

Earnings Reports·NASDAQ:BSX·Stock Market

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific shares slipped 0.2% to $77.49 in late-morning trading Friday, lagging a broader market rally. The stock remains under pressure after its electrophysiology segment missed sales estimates in the fourth quarter, triggering its steepest drop in over 25 years. Investors are watching for signs management can meet first-quarter growth targets. Trading volume stayed elevated as analysts revised forecasts.

6 February 2026

NASDAQ:BSX·Stock Market

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.

30 January 2026

Earnings Reports·NASDAQ:BSX·NASDAQ:PEN·Stock Market

Boston Scientific stock flat after Nalu buy closes; BSX investors eye Feb. 4 earnings

Boston Scientific shares were flat Tuesday afternoon after confirming the $600 million acquisition of Nalu Medical. The deal adds a peripheral nerve stimulation system to its pain-management lineup. Investors await the company’s Feb. 4 earnings release for 2026 guidance. BSX traded at $93.54, down 0.01% by 2:43 p.m. ET.

27 January 2026

Earnings Reports·NASDAQ:BSX·Stock Market

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific shares rose 1.7% to $94.12 Monday, outpacing medical-device peers and the S&P 500. Evercore reaffirmed its Outperform rating and $112 target, dismissing concerns about the $14.5 billion Penumbra acquisition. Investors await the Feb. 4 earnings call for updates on integration, financing, and demand trends. The Penumbra deal is expected to close in 2026.

26 January 2026

Earnings Reports·NASDAQ:BSX·Stock Market

Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts

Boston Scientific shares rose 1.3% to $92.51 Friday after Fitch upgraded its outlook to Positive, keeping A-/F1 ratings unchanged. The move follows Boston Scientific’s $14.5 billion Penumbra acquisition announcement. Trading volume topped recent averages. Investors await earnings and deal updates at the Feb. 4 call.

24 January 2026

NASDAQ:BSX·Stock Market

Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play

The FDA linked Boston Scientific’s AXIOS stent delivery systems to 167 serious injuries and three deaths, urging an immediate halt in use. Shares traded near $91.20 midday Wednesday, little changed as investors weighed the safety warning and the pending $14.5 billion Penumbra acquisition.

21 January 2026

NASDAQ:BSX·NASDAQ:PEN·Stock Market

Intuitive Surgical stock: Bernstein lifts ISRG target as JPM conference week begins

Intuitive Surgical shares closed Friday up 0.2% at $586.24 after Bernstein raised its price target to $740 and Goldman Sachs to $714. The company will present at the J.P. Morgan Healthcare Conference on Jan. 15, ahead of its expected earnings report around Jan. 22. Traders are watching for updates on procedure growth and hospital spending.

11 January 2026

NASDAQ:BSX·NASDAQ:ISRG·NYSE:SYK·Stock Market

Boston Scientific (BSX) stock slips in year-end pullback; February earnings loom

Boston Scientific shares fell 0.3% to $95.76 Monday, trading between $95.53 and $96.64 on light volume. U.S. stocks closed lower, with the S&P 500 down 0.35%. The company’s next earnings report is expected Feb. 4. Monday’s close leaves the stock about 12.5% below its 52-week high.

30 December 2025

Earnings Reports·NASDAQ:BSX·Stock Market

NASDAQ:BSX 30 December 2025 - 10 February 2026

Boston Scientific (BSX) stock price edges up after selloff; Farapulse data and March 28 CHAMPION-AF readout in focus

Boston Scientific stock price steadies after historic plunge as investors zero in on heart-rhythm outlook

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock flat after Nalu buy closes; BSX investors eye Feb. 4 earnings

Boston Scientific stock rises as Evercore taps BSX for a tactical list ahead of earnings

Boston Scientific stock price: BSX ends higher as Fitch turns credit outlook positive ahead of key catalysts

Boston Scientific stock steadies after FDA flags AXIOS stent issue; Penumbra deal still in play

Intuitive Surgical stock: Bernstein lifts ISRG target as JPM conference week begins

Boston Scientific (BSX) stock slips in year-end pullback; February earnings loom

Latest article

ASX 200 hits record close after strong week — what to watch next in Australian stocks

TSX logs best month since 2020, then slips Friday: what Toronto Stock Exchange investors watch next week

Shenzhen stocks finish the week higher — but ChiNext slides as Beijing policy week looms

Nifty slips below 25,200 to end week down 1.5% on NSE; GDP reset, PMIs in focus

Popular

Lam Research stock jumps 6% after Aletheia starts coverage with $260 target

Hungary’s Digital Lifeline: How Fiber, 5G, and Satellites Are Rewiring the Nation